Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Neurology
PDF) MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Disappointing topline results from high dose biotin study | MS Trust
PDF) Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)
High-dose biotin trial produces disappointing results | MS Ireland
MD1003 Aids Walking Speed in Progressive MS, But Carries Risks
High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study - EClinicalMedicine
MD1003 Aids Walking Speed in Progressive MS, But Carries Risks
High-Dose Biotin Fails MS Trial, Dashing Hopes | Everyday Health
MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis | Business Wire
Multiple Sclerosis and Biotin Treatment
Phase III Fail for MedDay's Multiple Sclerosis Treatment
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis: Expert Opinion on Drug Metabolism & Toxicology: Vol 12, No 3
MS News That Caught My Eye: Biotin, Opicinumab, Myelin, Tele-exercise
MD1003 (biotin) | MS Trust
MD1003 Aids Walking Speed in Progressive MS, But Carries Risks
France's MedDay says drug for MS falls at phase 3 hurdle -
High-Dose Biotin Fails to Improve Disability in Progressive MS
High-Dose Biotin Fails MS Trial, Dashing Hopes | Everyday Health
High-Dose Biotin Fails in Phase 3 for Progressive Multiple Sclerosis
Disappointing topline results from high dose biotin study | MS Trust
Could High-Dose Biotin Be Used as a Treatment for Multiple Sclerosis? - Multiple Sclerosis News Today
High-Dose Biotin Fails MS Trial, Dashing Hopes | Everyday Health
MedDay's MD1003, a Biotin, Shows 'Remarkable' Efficacy in Treating Inactive but Progressive MS in Clinical Trials - Multiple Sclerosis News Today
High-Dose Biotin Fails MS Trial, Dashing Hopes | Everyday Health
MD1003 (biotin) | MS Trust
Need to Know: High-dose Biotin Protocol for Multiple Sclerosis
